Skip to main content
. Author manuscript; available in PMC: 2021 Jul 22.
Published in final edited form as: Neuropharmacology. 2017 Sep 6;126:190–199. doi: 10.1016/j.neuropharm.2017.09.007

Figure 3.

Figure 3.

Effects of CAB2-015 or BAK4-54 on oxycodone self-administration dose-response curve in rats. A: Pretreatment with CAB2-015 (10 mg/kg, i.p.) or BAK4-54 (10 mg/kg, i.p.) significantly shifted the dose-response curve downward; B: Calculated oxycodone intake, indicating that CAB2-015 or BAK4-54 significantly shifted the dose-intake curves downward. *p<0.05, **p<0.01, compared to the vehicle group. N=7-8/group.